Gilead claims victory in Sovaldi arbitration

Gilead Sciences Inc. (NASDAQ:GILD) disclosed in an SEC filing that an arbitration panel ruled Roche (SIX:ROG; OTCQX:RHHBY) failed to establish its claims to Gilead's HCV drug Sovaldi sofosbuvir. Roche initiated arbitration against Gilead in March 2013, claiming that Roche had an exclusive license to the drug under a 2004 deal between Roche's Hoffman-La Roche Inc. unit and Pharmasset Inc. Under that deal, Roche got rights to develop PSI-6130, a cytidine analog and its prodrugs, to treat HCV infection. Roche claimed that sofosbuvir, a prodrug of a uridine monophosphate analog, is a prodrug of PSI-6130. The pharma also claimed it had an exclusive license to a patent covering the drug. ...